Peroxisome proliferator-activated receptor-gamma as a potential therapeutic target in the treatment of preeclampsia.
AffiliationAnu Research Centre, University College Cork, Cork University Maternity Hospital,, Wilton, Cork, Ireland. firstname.lastname@example.org
Blood Pressure/*drug effects
MetadataShow full item record
CitationHypertension. 2011 Aug;58(2):280-6. Epub 2011 Jun 20.
AbstractPreeclampsia is a multisystemic disorder of pregnancy characterized by hypertension, proteinuria, and maternal endothelial dysfunction. It is a major cause of maternal and perinatal morbidity and mortality and is thought to be attributable, in part, to inadequate trophoblast invasion. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) is a ligand-activated transcription factor expressed in trophoblasts, and the vasculature of which activation has been shown to improve endothelium-dependent vasodilatation in hypertensive conditions. We investigated the effects of the administration of a PPAR-gamma agonist using the reduced uterine perfusion pressure (RUPP) rat model of preeclampsia. The selective PPAR-gamma agonist, rosiglitazone, was administered to pregnant rats that had undergone RUPP surgery. To investigate whether any observed beneficial effects of PPAR-gamma activation were mediated by the antioxidant enzyme, heme oxygenase 1, rosiglitazone was administered in combination with the heme oxygenase 1 inhibitor tin-protoporphyrin IX. RUPP rats were characterized by hypertension, endothelial dysfunction, and elevated microalbumin:creatinine ratios. Rosiglitazone administration ameliorated hypertension, improved vascular function, and reduced the elevated microalbumin:creatinine ratio in RUPP rats. With the exception of microalbumin:creatinine ratio, these beneficial effects were abrogated in the presence of the heme oxygenase 1 inhibitor. Administration of a PPAR-gamma agonist prevented the development of several of the pathophysiological characteristics associated with the RUPP model of preeclampsia, via a heme oxygenase 1-dependent pathway. The findings from this study provide further insight into the underlying etiology of preeclampsia and a potential therapeutic target for the treatment of preeclampsia.
- Evidence implicating peroxisome proliferator-activated receptor-γ in the pathogenesis of preeclampsia.
- Authors: McCarthy FP, Drewlo S, English FA, Kingdom J, Johns EJ, Kenny LC, Walsh SK
- Issue date: 2011 Nov
- Expression of heme oxygenase-1 in human vascular cells is regulated by peroxisome proliferator-activated receptors.
- Authors: Krönke G, Kadl A, Ikonomu E, Blüml S, Fürnkranz A, Sarembock IJ, Bochkov VN, Exner M, Binder BR, Leitinger N
- Issue date: 2007 Jun
- Activation of PPAR-γ ameliorates pulmonary arterial hypertension via inducing heme oxygenase-1 and p21(WAF1): an in vivo study in rats.
- Authors: Zhang D, Wang G, Han D, Zhang Y, Xu J, Lu J, Li S, Xie X, Liu L, Dong L, Li M
- Issue date: 2014 Mar 7
- Oral intake of rosiglitazone promotes a central antihypertensive effect via upregulation of peroxisome proliferator-activated receptor-gamma and alleviation of oxidative stress in rostral ventrolateral medulla of spontaneously hypertensive rats.
- Authors: Chan SH, Wu KL, Kung PS, Chan JY
- Issue date: 2010 Jun
- Peroxisome proliferator-activated receptor-gamma agonists suppress tissue factor overexpression in rat balloon injury model with paclitaxel infusion.
- Authors: Park JB, Kim BK, Kwon YW, Muller DN, Lee HC, Youn SW, Choi YE, Lee SW, Yang HM, Cho HJ, Park KW, Kim HS
- Issue date: 2011